Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Venglustat for treating late onset GM2 gangliosidosis, GM1 gangliosidosis and other ultra-rare disease	Venglustat	GM1 gangliosidosis , GM2 gangliosidosis	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2023	View \| Download
Venetoclax with dexamethasone for previously treated relapsed/refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download
Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line	Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Venetoclax in combination with azacitidine for myelodysplastic syndrome	Azacitidine (Vidaza; CC-486) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2023	View \| Download
Venetoclax in combination with a hypomethylating agent or low dose cytarabine for newly diagnosed acute myeloid leukaemia	hypomethylating agent , Low-dose cytarabine , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Venetoclax in addition to ibrutinib for relapsed mantle cell lymphoma – second-line and beyond	Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2020	View \| Download
Vemurafenib (Zelboraf) for BRAF V600 mutation positive melanoma; completely resected but at high risk of recurrence	Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204)	Melanoma	Skin Cancer	2017	View \| Download
Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line	Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664)	Breast cancer	Breast Cancer	2017	View \| Download
Veliparib in addition to carboplatin and paclitaxel for epithelial ovarian, fallopian tube, or primary peritoneal cancer	Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download